Tag: KDC-MN-054

  • CX-516 (Ampalex)

    Benzoylpyrrolidine ampakine

    The first ampakine to enter human clinical trials, developed at Cortex Pharmaceuticals as a mechanism prototype with limited efficacy.

    Abstract

    CX-516 (Ampalex; 1-(quinoxalin-6-ylcarbonyl)piperidine; CAS 154235-83-3; molecular formula C14H15N3O; molecular weight 241.29) was the first ampakine compound to enter human clinical trials, developed at Cortex Pharmaceuticals (now RespireRx Pharmaceuticals) under license from Gary Lynch and Gary Rogers at the University of California, Irvine. The compound is a benzoylpyrrolidine class AMPA receptor positive allosteric modulator. CX-516 advanced through Phase 2 trials in mild cognitive impairment, schizophrenia (cognitive symptoms), and fragile X syndrome, with mixed results that did not support advancement to Phase 3. The compound has poor pharmacokinetic properties (very short plasma half-life, approximately 1 to 2 hours, and low oral bioavailability) which limit its clinical utility despite mechanistic interest. CX-516 retains research utility as an AMPA potentiator probe but is largely superseded by later-generation compounds (CX-546, CX-614, and others). The compound is sold as a research chemical in jurisdictions where it is not scheduled.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.